Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 23 of 23
Jan 9, 2026Insmed reported that Brinsupri generated $144.6 million in sales in the first full quarter of 2025, surpassing expectations for the treatment of bronchiectasis. This strong initial commercial performance highlights continued demand for innovative therapies in chronic lung conditions.
TCB Team
Jan 9, 2026Following a late-stage clinical trial failure for Gohibic, an emergency use authorized COVID-19 antibody, InflaRx is restructuring to reduce spending and shift focus within its therapeutic pipeline.
TCB Team
Jan 9, 2026Eli Lilly has acquired Ventyx Biosciences for $1.2 billion to bolster its drug pipeline with an oral NLRP3 inhibitor showing promising mid-stage clinical data. Potential applications span cardiovascular disease, Parkinson’s disease, and autoimmune conditions, reinforcing Lilly's position in inflammation-focused therapies.
TCB Team
Jan 8, 2026New clinical data suggest bepirovirsen could offer a finite treatment alternative to lifelong antivirals for chronic hepatitis B infection. Achieving functional cure after six months marks a potential paradigm shift in this infectious disease area.
TCB Team
Jan 7, 2026Dark Blue Therapeutics' lead asset is a small-molecule degrader of MLLT1 and MLLT3 proteins currently being tested in acute myeloid leukemia (AML). This acquisition is part of Amgen's strategic push into innovative cancer therapies in the hematology space.
TCB Team
Jan 7, 2026The acquisition, valued at up to $840 million, strengthens Amgen's oncology pipeline with a drug candidate addressing challenging leukemia markers, signaling commitment to hematologic cancers.
TCB Team
Jan 7, 2026Ventyx Biosciences is developing oral treatments targeting autoimmune conditions, complementing Lilly's expanding focus on this therapeutic area. The potential deal highlights ongoing consolidation in biotech.
TCB TeamMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.